AstraZeneca (United Kingdom)
Papers in the tracked journals with an author at AstraZeneca (United Kingdom): per year and category, where they are published, the institutions its researchers write with, and its most-cited papers. A paper counts as corporate when at least one of its authors is affiliated with an institution that OpenAlex classifies as a company; it counts once for each company among its authors' affiliations. Universities are the institutions OpenAlex classifies as education. Also as Markdown.
Key findings#
- From 2017 to 2026 (so far), authors at AstraZeneca (United Kingdom) took part in 46 papers in the tracked journals, most of them in health economics and policy (22), AI (13) and statistics (10).
- 5 of them were published in 2025, against 2 in 2017.
- Since 2023, the institutions with the most of these papers were AstraZeneca (Sweden) (7), University of Leicester (5) and University of Cambridge (4).
- The journals publishing most of them were Nature Machine Intelligence (5), BMC Medical Research Methodology (4) and PharmacoEconomics - Open (4).
- The most-cited of them is “Common pitfalls and recommendations for using machine learning to detect and prognosticate for COVID-19 using chest radiographs and CT scans” (Nature Machine Intelligence, 2021), with 1,045 citations.
- Since 2023, papers in the tracked journals cited 14 of its papers 71 times; 96% of those links came from papers with a university author and 3% from its own papers.
- Its own papers since 2023 cite archived papers 33 times, 39% of them papers with a company author.
- Across everything OpenAlex indexes, AstraZeneca (United Kingdom) has 18,858 works with 2,519,474 citations (h-index 552).
- The tracked journals hold 37 of its 9,981 works in OpenAlex from 2017 to 2025 (0.4%).
- Its main research topics in OpenAlex are Asthma and respiratory diseases (1,416), Lung Cancer Treatments and Mutations (1,334) and Chronic Obstructive Pulmonary Disease (COPD) Research (1,227).
Papers per year#
20172026 (so far)
| Category | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (so far) |
|---|---|---|---|---|---|---|---|---|---|---|
| Health Economics and Policy | 2 | 0 | 1 | 3 | 1 | 3 | 3 | 4 | 2 | 3 |
| AI | 0 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 4 |
| Statistics | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 2 | 2 | 2 |
| Management | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| All categories | 2 | 0 | 3 | 5 | 3 | 7 | 5 | 7 | 5 | 9 |
Where the papers come from#
| # | Journal | Papers |
|---|---|---|
| 1 | Nature Machine Intelligence | 5 |
| 2 | BMC Medical Research Methodology | 4 |
| 3 | PharmacoEconomics - Open | 4 |
| 4 | The European Journal of Health Economics | 3 |
| 5 | Health and Quality of Life Outcomes | 2 |
| 6 | Technological Forecasting and Social Change | 1 |
| 7 | Health Policy | 1 |
| 8 | Knowledge-Based Systems | 1 |
| 9 | PharmacoEconomics | 1 |
| 10 | Patient | 1 |
| # | Institution | Papers |
|---|---|---|
| 1 | AstraZeneca (Sweden) | 7 |
| 2 | University of Leicester | 5 |
| 3 | University of Cambridge | 4 |
| 4 | AstraZeneca (United States) | 3 |
| 5 | University Medical Center Groningen | 3 |
| 6 | University of Groningen | 3 |
| 7 | AstraZeneca (Canada) | 2 |
| 8 | AstraZeneca (Spain) | 2 |
| 9 | Health Economics and Outcomes Research (United Kingdom) | 2 |
| # | Country | Papers |
|---|---|---|
| 1 | United Kingdom | 26 |
| 2 | Sweden | 9 |
| 3 | United States | 5 |
| 4 | Australia | 4 |
| 5 | Germany | 4 |
| 6 | Canada | 3 |
| 7 | China | 3 |
| 8 | Netherlands | 3 |
| 9 | Brazil | 2 |
| 10 | Egypt | 2 |
| # | Keyword | Papers |
|---|---|---|
| 1 | cost-effectiveness | 5 |
| 2 | quality-adjusted life years | 4 |
| 3 | adjuvant therapy | 3 |
| 4 | incremental cost-effectiveness ratio | 3 |
| 5 | cancer clinical trials | 2 |
| 6 | chronic kidney disease | 2 |
| 7 | cross-national comparison | 2 |
| 8 | denoising diffusion probabilistic models | 2 |
| 9 | early breast cancer | 2 |
| 10 | health technology assessment | 2 |
Most-cited papers#
Who cites its research#
| # | Institution | Kind | Country | Links |
|---|---|---|---|---|
| 1 | University of Cambridge | University | United Kingdom | 8 |
| 2 | Imperial College London | University | United Kingdom | 7 |
| 3 | The Alan Turing Institute | Research facility | United Kingdom | 5 |
| 4 | King's College London | University | United Kingdom | 4 |
| 5 | University of Manchester | University | United Kingdom | 3 |
| 6 | University of Oxford | University | United Kingdom | 3 |
| 7 | Royal Brompton Hospital | Healthcare | United Kingdom | 3 |
| 8 | Tecnalia | Other | Spain | 3 |
| 9 | University College London | University | United Kingdom | 3 |
| 10 | Indian Statistical Institute | University | India | 3 |
What its papers cite#
| # | Institution | Kind | Country | Links |
|---|---|---|---|---|
| 1 | Durham University | University | United Kingdom | 5 |
| 2 | Bristol-Myers Squibb (United Kingdom) | Company | United Kingdom | 3 |
| 3 | Portland State University | University | United States | 2 |
| 4 | Merck & Co., Inc., Rahway, NJ, USA (United States) | Company | United States | 2 |
| 5 | Merck KGaA, Darmstadt (Germany) | Company | Germany | 2 |
| 6 | Chinese Academy of Sciences | Government | China | 2 |
| 7 | University of Manchester | University | United Kingdom | 2 |
| 8 | Bristol-Myers Squibb (United States) | Company | United States | 2 |
| 9 | Health Economics and Outcomes Research (United Kingdom) | Company | United Kingdom | 2 |
In OpenAlex#
| Item | Value |
|---|---|
| Type | Company |
| Location | Cambridge, England, United Kingdom |
| Units listed in OpenAlex | 18 |
| Works in OpenAlex | 18,858 |
| Citations | 2,519,474 |
| h-index | 552 |
| i10-index | 26,537 |
| 2-year mean citedness | 8.17 |
| Website | www.astrazeneca.com |
| ROR | ror.org/04r9x1a08 |
| OpenAlex | openalex.org/I105036370 |
| # | Topic | Field | Works |
|---|---|---|---|
| 1 | Asthma and respiratory diseases | Medicine | 1,416 |
| 2 | Lung Cancer Treatments and Mutations | Medicine | 1,334 |
| 3 | Chronic Obstructive Pulmonary Disease (COPD) Research | Medicine | 1,227 |
| 4 | Computational Drug Discovery Methods | Computer Science | 1,062 |
| 5 | Cancer Immunotherapy and Biomarkers | Medicine | 951 |
| Year | Works in OpenAlex | Citations received | In the tracked journals | Share |
|---|---|---|---|---|
| 2026 (so far) | 1,131 | 69,470 | 9 | 0.8% |
| 2025 | 1,552 | 83,542 | 5 | 0.3% |
| 2024 | 1,442 | 79,805 | 7 | 0.5% |
| 2023 | 1,367 | 72,909 | 5 | 0.4% |
| 2022 | 1,123 | 69,893 | 7 | 0.6% |
| 2021 | 1,102 | 68,049 | 3 | 0.3% |
| 2020 | 1,025 | 52,643 | 5 | 0.5% |
| 2019 | 879 | 41,737 | 3 | 0.3% |
| 2018 | 793 | 36,545 | 0 | 0.0% |
| 2017 | 698 | 33,068 | 2 | 0.3% |
Cite this page
Scholar4AI. (2026). AstraZeneca (United Kingdom). Journal and Conference Research Rankings. Retrieved November 5, 2026, from https://scholar4ai.com/companies/astrazeneca-united-kingdom
@misc{scholar4ai-companies-astrazeneca-united-kingdom,
author = {{Scholar4AI}},
title = {AstraZeneca (United Kingdom)},
year = {2026},
howpublished = {\url{https://scholar4ai.com/companies/astrazeneca-united-kingdom}},
urldate = {2026-11-05},
note = {Journal and Conference Research Rankings; data from OpenAlex (CC0); licensed CC BY-NC 4.0}
}